January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Medicilon to speak at YAFO ACCESS ASIA BD Forum @ JPM 2026.
View more information at: https://biotochina.org/
创始人、董事长兼CEO
Founder, Chairman and CEO
1986年毕业于中国药科大学,获药学硕士学位并于1994年毕业于美国俄克拉何马州立大学，获药理学及毒理学博士学位，中欧商学院EMBA。毕业后从事多年药物的药理、毒理及生物化学研究，在设计心血管药物、抗艾滋和抗癌新药的药代动力学和代谢方面有着很深的造诣。2004年初回国创办上海美迪西生物医药股份有限公司。公司已经为2000多家biotech、制药公司及大学和研究所提供新药研发服务，并帮助和支持超过580件创新药IND在中国、美国、澳大利亚、欧盟和韩国等获批进入临床研究。现担任中国药理学会药物代谢动力学专业委员会委员、上海欧美同学会生物医药分会会长及上海浦东生物医药协会副理事长等职务，同时还受聘为中国药科大学生命科学院客座教授。个人殊荣有：浦东新区“创业人才”奖(2005年)；上海市浦江人才(2007年)；上海市领军人才(2009年)；上海“归国创业精英奖(2009年)；国务院邀请的北戴河休假专家(2009年)；上海市优秀技术带头人(2011年)；上海张江高新技术产业开发区建设突出贡献个人(2011年)；获得常州市“龙城英才计划”领军人才(2012年)；上海高科技园区“最热情药谷人奖”。Dr. Chen is Chairman, founder and CEO of Medicilon. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Prior to founding Medicilon, Dr. Chen had work experience in the USA, as a Staff Investigator at Department of Pharmacokinetics and Metabolism in Vertex Pharmaceuticals and as the Director of Pharmaceutical Department at Parker Hughes Cancer Center.In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University. Medicilon has provided drug development services to over 2,000 clients worldwide and has assisted in the approval of 588 IND applications for clinical trials globally.
首席商务官
Chief Business Officer
本科硕士博士均毕业于中国药科大学，博士期间曾在日本富山医科药科大学和汉药研究所资源开发部参与合作研究，随后在中科院上海药物所博士后流动站工作，有30多年中药新药和化学药产品开发研究经验。曾于1991年荣获国家中医药管理局科学技术进步一等奖，1992年荣获国家科学技术进步一等奖。而后在汇仁集团研发部任研究中心主任，荣获2004年汇仁公司“十佳”女员工和2006年被江西省经贸委评为“十五”全省企业技术中心管理先进个人。后于2008年7月加入美迪西，先后任中国区市场开拓总监、副总裁、商务发展部副总裁。
Dr. Cai completed her whole high-level education at China Pharmaceutical University from Bachelor to Ph.D. Conducted research with Medical University of Toyama and Institution of Natural Medicine cooperatively. Later, she worked at Chinese Academy of Sciences Shanghai Institute of Materia Medica.
Over 30 years of dedication in new drug development and research. Was awarded the first Prize for Science and Technology Progress by the State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. Worked for Huiren Group as director of R&D Center for 5 years. Was awarded one of the top 10 employees by Huiren Group in 2006 and Excellent Management Individual of Provincial Technological Center during the “10th-five-year “by Jiangxi Province.
Dr. Cai joined Medicilon in July 2008 and took on the position of BD Head of Chinese market and then Vice President of BD Department.
执行副总裁兼美国公司总裁
President at Medicilon USA Corp
美国纽约爱因斯坦医学院分子细胞生物学博士，曾连续四年荣获“SAPA-NE服务奖”，获评“北京海外人才”、“南京大学优秀青年教师”等荣誉称号。
林博士学术背景深厚，曾在美国阿尔伯特·爱因斯坦医学院Raju Kucherlapati’s 实验室、哈佛大学医学院从事分子遗传学研究等，曾任哈佛大学医学院遗传和基因组学研究中心基因工程实验室总监，在MCB、JBC等国际权威期刊上发表24篇论文，并荣获多项发明专利。多年学术浸润，使他在细胞生物学、分子生物学、免疫学、药理学、抗体药物发现和开发、发育生物学、生物信息学以及功能遗传学和基因组学等领域沉淀了极高的学术造诣和扎实的技术功底。
深耕生物医药研发领域近40载，林博士不仅在学术界产生了重要影响，也为全球生物医药行业的发展做出了卓越贡献，曾为跨国公司缔造子公司，组建多个科学团队，领导百余个药物项目研发，在细胞生物学、分子遗传学、基因工程的肿瘤小鼠模型研究与应用领域颇有研究，在抗体药物研发、杂交瘤细胞抗体和人噬菌体抗体库的建立、抗体基因工程、抗体人源化和亲和力提高与成熟，以及哺乳动物细胞抗体药物生产上, 积累了丰富的项目开发经验和管理智慧。加入美迪西之前，林博士曾担任惠氏制药资深科学家Ⅱ级、首席科学家Ⅰ级和Ⅱ级以及分子遗传学实验室主任；辉瑞制药首席科学家Ⅱ级；盛诺基医药生物和抗体药物研发资深副总裁；百奥赛图资深副总裁兼Biocytogen Boston Corp（BBC）首席执行官等。
Dr. Qingcong Lin holds a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine of Yeshiva University. He has conducted molecular genetics research in Raju Kucherlapati’s laboratory at Albert Einstein College of Medicine and Harvard Medical School. He has served as the Director of the Gene Modification Laboratory at Harvard-Partners Center for Genetics and Genomics (HPCGG). He has also published 24 papers in prestigious international journals such as MCB, JBC and holds multiple invention patents.
Having worked in the pharmaceutical R&D field for nearly 40 years, Dr. Lin has not only made significant impacts in academics but also contributed remarkably to the global pharmaceutical industry. Before joining Medicilon, Dr. Lin held positions such as Senior Scientist II, Principal Research Scientist I & II, and Director of Molecular Genetics Laboratory at Wyeth Research; Principal Research Scientist II and Group Leader at Pfizer Research; Senior VP of Biology and Antibody R&D at Shenogen Pharma Group; and SVP of Beijing Biocytogen, CEO of Biocytogen Boston Corp. Dr. Lin has established subsidiary companies for multinational corporations, built multiple scientific teams, and has excellent drug R&D experience gained in more than 100 projects. Dr. Lin has accumulated rich experience in project development and management in antibody drug development, establishment of hybridoma cell antibodies and human phage antibody libraries, antibody gene engineering, antibody humanization, affinity maturation, and mammalian cell antibody drug production.
药物发现事业部兼药学研究事业部总裁
President of Drug Discovery and CMC Divisions
南开大学有机化学硕士，美国俄亥俄州立大学 （The Ohio State University）生物化学硕士，有机化学博士，国家级海外高层次专家；横跨国际大型药企、CRO和Biotech技术公司，在生物医药领域耕耘25年，积累了研发、运营和管理的丰富经验。
段博士亲自主持了从立项、PCC、IND研究和申报、直至临床研究的全链条药物研发。不仅理解药物开发流程，而且广泛涉猎药物化学、CMC、生物学、药理学、药代动力学、毒理学等多个领域，掌握各种数据解读，促进高效决策。此外，作为核心管理者，段博士擅长领导跨部门、跨学科团队协作，有效整合多方资源，推进研发管线，在抗病毒、抗肿瘤、代谢性疾病、免疫学等疾病领域分别将多个分子推进到 IND和临床研究的不同阶段，并有两款药物获得FDA批准上市。段博士跟紧生物医药技术前沿，对共价抑制剂，ADC，PROTAC、小核酸等领域有着深刻的见解。段博士拥有34项发明专利，并在权威学术期刊上发表了28篇经过同行评审的高质量学术论文。
加入美迪西之前，段博士曾任GSK首席科学家，积累了10年小分子药物研发经验；在辉源生物担任副总裁期间，完成从0-1构建药物化学服务部，为国内外药企提供了强有力的药物研发支持直至公司被药明康德收购。因此，深谙CRO“质量-效率-交付”的服务宗旨；作为越之康泰生物的共同创始人、首席执行官及首席科学官，领导公司运营、研发及临床开发，成功推动了公司资产在2020年被收购；在纳肽得生物担任首席执行官期间，主导小核酸(siRNA)技术平台建设和项目管线开发，并通过商务BD，成功完成了管线对外授权（license out）和交易。这些丰富经历和卓越成就，将为美迪西的发展注入强劲动力。
Dr. Maosheng Duan holds a Master’s degree in Organic Chemistry from Nankai University in Tianjin, China, as well as a Ph.D. in Organic Chemistry and a Master’s degree in Biochemistry from The Ohio State University in the USA. With over 25 years of experience in the pharmaceutical and biotech industry, Dr. Duan has worked across international big pharma, CROs, and biotech companies, gaining extensive expertise in R&D, operations, and management. Prior to joining Medicilon, Dr. Duan held key leadership roles at prominent organizations, including GSK, HD Biosciences, YueZhi KangTai Biomedicine, and NanoPeptide Biotechnology.
Dr. Duan has directed and led the entire drug research and development process, from project initiation and PCC nomination to IND enabling, filing, and clinical studies. He possesses not only a broad understanding of the drug R&D process but also deep expertise in medicinal chemistry, CMC, biology, pharmacology, pharmacokinetics, toxicology, and clinical regulations. Additionally, Dr. Duan is highly skilled in interpreting diverse types of data to facilitate efficient decision-making.
As a core leader, Dr. Duan excels in guiding cross-functional and interdisciplinary teams, effectively integrating resources to advance R&D pipelines. He has successfully progressed multiple molecules through various stages, from IND filings to clinical studies and NDAs, in the fields of antiviral, antitumor, metabolic diseases, and immunology, with two FDA-approved drugs. Dr. Duan remains at the forefront of biomedical technologies, offering unique insights into cutting-edge areas such as covalent inhibitors, ADCs, PROTACs, and RNAi. His accomplishments include 34 invention patents and 28 publications in peer-reviewed journals.
时间 & 地点: 2026 年 1 月 11 日 | 旧金山洲际酒店
更多活动详情请至: https://biotochina.org/
Date & Venue: January 11, 2026 | InterContinental San Francisco
View more information at: https://biotochina.org/